EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Secondary Prophylaxis of Cirrhotic Gastric Variceal Bleeding: Addition of Non‐Selective Beta‐Blockers to Endoscopic Combined Treatment

Ling Wu iD, Xiaoquan Huang, Feng Li, Siyu Jiang, Liyuan Ni, Yingjie Ai, Detlef Schuppan, Shiyao Chen

United European Gastroenterology Journal · 2025

DOI: 10.1002/ueg2.12739 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von Ling Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Esophageal and Gastric Varices, Gastrointestinal Hemorrhage, Adrenergic beta-Antagonists, Liver Cirrhosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Shanghai Committee of Science and Technology, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It remains unclear whether the addition of non‐selective beta‐blockers (NSBB) provides further benefit after combined use of tissue adhesive and endoscopic variceal ligation for bleeding gastroesophageal varices.

Objective

This is the first cohort study comparing the secondary prophylactic efficacy of adding NSBB to combined endoscopic treatment in cirrhotic patients with gastric varices (without inclusion of isolated gastric varices [IGVs], which are rare in patients with cirrhosis without splanchnic thrombosis).

Methods

We retrospectively analyzed two matched large cohorts of cirrhotic patients with gastric varices who received combined endoscopic treatment and were assigned to receive NSBB treatment or not as secondary prophylaxis. Further sub‐analyses were performed. The 5‐year overall survival and rebleeding rates were compared.

Results

A total of 490 patients were enrolled, 130 of whom took NSBB. After propensity score matching (PSM), both groups comprised 130 patients. No significant difference between the NSBB and non‐NSBB groups was observed regarding 5‐year survival (87.40% vs. 83.64%, HR 0.62, 95% CI 0.33–1.17), while NSBB decreased the 5‐year rebleeding rate from 45.7% to 30.64% (HR 0.57, 95% CI 0.39–0.82). The same was true when comparing the 2 groups after PSM. NSBB (HR 0.54, 95% CI 0.37–0.79) and splenectomy (HR 0.65, 95% CI 0.44–0.96) independently reduced rebleeding but did not affect survival. In patients without splenectomy, NSBB treatment improved survival (HR 0.43, 95% CI 0.21–0.89) and reduced rebleeding (HR 0.52, 95% CI 0.34–0.78).

Conclusion

We show for the first time that adding NSBB to combined endoscopic therapy significantly reduced recurrent variceal bleeding in cirrhotic patients but did not improve overall survival, except for patients without splenectomy. The addition of NSBB for patients receiving combined endoscopic treatment of gastroesophageal varices provides benefits but does not prolong overall survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal and Gastric VaricesGastrointestinal HemorrhageAdrenergic beta-AntagonistsLiver CirrhosisSecondary PreventionHumansMaleFemaleMiddle AgedRetrospective StudiesLigationAgedTreatment OutcomeCombined Modality TherapyRecurrencePropensity ScoreTissue Adhesives

Stichwörter der Autor:innen

NSBBcirrhosisgastric varicesgastroesophageal varicesgastrointestinal hemorrhageligationportal hypertensionrebleedingsurvival analysistissue adhesive

Substanzen

Adrenergic beta-AntagonistsTissue Adhesives

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Institute of Translational Immunology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
  • Center of Evidence-based Medicine, Fudan University, Shanghai, China.
  • Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Ling Wu

Förderung

  • National Key Research and Development Program of China
  • Shanghai Committee of Science and Technology
  • Deutsche Forschungsgemeinschaft
  • HORIZON EUROPE European Research Council

Zitieren

APA

Wu, L., Huang, X., Li, F., Jiang, S., Ni, L., Ai, Y., Schuppan, D., & Chen, S. (2025). Secondary Prophylaxis of Cirrhotic Gastric Variceal Bleeding: Addition of Non‐Selective Beta‐Blockers to Endoscopic Combined Treatment. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12739

Vancouver

Wu L, Huang X, Li F, Jiang S, Ni L, Ai Y, et al. Secondary Prophylaxis of Cirrhotic Gastric Variceal Bleeding: Addition of Non‐Selective Beta‐Blockers to Endoscopic Combined Treatment. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.12739

BibTeX
@article{Wu2025,
  author = {Wu, Ling and Huang, Xiaoquan and Li, Feng and Jiang, Siyu and Ni, Liyuan and Ai, Yingjie and Schuppan, Detlef and Chen, Shiyao},
  title = {Secondary Prophylaxis of Cirrhotic Gastric Variceal Bleeding: Addition of Non‐Selective Beta‐Blockers to Endoscopic Combined Treatment},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  doi = {10.1002/ueg2.12739}
}
Kostenlos starten →